Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 10,705 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Haematologic Disease Clear all

Conditions: Hematologic Diseases
Interventions: HLA typing; Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Interventions: Atezolizumab, Guadecitabine; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Hematologic Malignancy, Myeloid Malignancy
Interventions: Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Cyclosporine, Cyclophosphamide, Fludarabine, Methotrexate, Total Body Irradiation (radiation treatment), Bone marrow infusion, Busulfan, Thiotepa; Drug · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hemophilia A, Hemophilia B
Interventions: ALN-AT3SC, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anemia, Kidney Disease
Interventions: AKB-6548, Placebo; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 28
States / cities: Pine Bluff, Arkansas • Covina, California • Los Angeles, California + 25 more

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
Interventions: Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis, Leukapheresis, Fludarabine Phosphate; Biological · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2039
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hematologic Malignancies
Interventions: Non-neutropenic Diet; Other
Lead sponsor: Duke University; Other
Eligibility: 20 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Interventions: Luspatercept; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Stanford, California + 9 more

Conditions: Immune Thrombocytopenia
Interventions: Discontinuation of eltrombopag; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Relapsed/Refractory Systemic Light Chain Amyloidosis
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 8
States / cities: Duarte, California • Denver, Colorado • Boston, Massachusetts + 5 more

Conditions: Leukemia, Other
Interventions: Not listed
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 5
States / cities: Miami, Florida • Miami Beach, Florida • Rochester, Minnesota + 2 more

Conditions: Immune Thrombocytopenia
Interventions: Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 18 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more

Conditions: Leukemia, Leukemia, B-Cell, Chronic
Interventions: Dose Level 1, Dose Level 2, Dose Level 2- Fixed Dose; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Pembrolizumab, Radiation Therapy; Biological · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Myelofibrosis, Anemia
Interventions: Placebo, Elritercept; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 30
States / cities: Gilbert, Arizona • Glendale, California • Whittier, California + 23 more

Conditions: Hematologic Malignancies
Interventions: Fludarabine, Busulfan, Thymoglobulin, Total Body Irradiation, Umbilical Cord Blood; Drug · Radiation · Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Purpura, Thrombocytopaenic, Idiopathic
Interventions: Eltrombopag; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Tucson, Arizona • Washington D.C., District of Columbia • Detroit, Michigan + 2 more

Conditions: Myelofibrosis
Interventions: Busulfan, Fludarabine, Thymoglobulin (ATG); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: Vosaroxin, Decitabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: PI3K-beta Inhibitor GSK2636771; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Iron-deficiency, Iron Deficiency Anemia
Interventions: phytic acid; Dietary Supplement
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: GTB-360; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Interventions: NX-5948; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Duarte, California • San Francisco, California • Denver, Colorado + 15 more

Search by objective public record fields.

HLA Matching - Unrelated Umbilical Cord Blood Transplantation

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Hairy Cell Leukemia Patient Data Registry

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies

LENS - Long-term Eltrombopag Observational Study

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies